Smallpox Vaccine
IMVAMUNE is promising candidate as third generation smallpox vaccine
Published in Vaccine Weekly, May 24th, 2006
According to recent research published in the journal Vaccine, "A Phase I trial was performed to investigate the safety and immunogenicity of the third generation smallpox vaccine MVA-BN (IMVAMUNE), a highly attenuated clone derived from the Modified Vaccinia Virus Ankara strain 571, in naive and pre-immunized subjects. A total of 86 healthy subjects received the vaccine in five groups using different doses and routes of administration. All 38 subjects seroconverted in the groups receiving the highest dose (108 TCID50 )."
"All vaccinations were well...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-05-24)
More Articles from Vaccine Weekly
- Clonorchiasis Vaccine
DNA encoding cysteine proteinase protects against clonorchiasis - Lyme Disease Vaccine
Oral vaccine reduces Borrelia burgdorferi carriage and protects against Lyme disease - Plague Vaccine
Intranasal Protollin/F1-V vaccine protects against plague infection - Tuberculosis Vaccine
Lipid-encapsulated BCG induces long-term protection against tuberculosis - Adenoviral Vector
Replication properties of human adenovirus in different animal species described - Alzheimer Disease Vaccine
A-beta-induced meningoencephalitis linked to T cell-dependent clearance of A-beta - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
